FinscoFinsco

Arbutus Biopharma (US.ABUS)

Capital Allocation Audit · Period: 2010 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.ABUS · YoY: 2026 Q1 vs 2025 Q1

MetricValueYoY
FCF Conversion100.0%→
ROE65.2%↑
Cash Conversion-4.8%→
D/E Ratio0.00↑
Gross Margin0.0%↓
US.ABUS (Arbutus Biopharma) | YoY: 2026 Q1 vs 2025 Q1


Metric            Value  YoY
----------------------------
FCF Conversion   100.0%    →
ROE               65.2%    ↑
Cash Conversion   -4.8%    →
D/E Ratio          0.00    ↑
Gross Margin       0.0%    ↓
Key Metrics
US.ABUS (Arbutus Biopharma) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY
----------------------------
FCF Conversion 100.0% →
ROE 65.2% ↑
Cash Conversion -4.8% →
D/E Ratio 0.00 ↑
Gross Margin 0.0% ↓

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies